Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine

Pediatric Infectious Disease Journal

Volumn 24, Issue 6, 2005, Pages 481-488

  Dennehy, Penelope H ^a   Brady, Rebecca C ^b   Halperin, Scott A ^c   Ward, Richard L ^b   Alvey, Justin C ^d   Fischer Jr , Francis H ^e   Innis, Bruce L ^f   Rathfon, Hal ^f   Schuind, Anne ^f   De Vos, Beatrice ^g  

^a RHODE ISLAND HOSPITAL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d Wee Care Pediatrics   (United States)

^e Holston Medical Group   (United States)

^f GLAXOSMITHKLINE   (United States)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Immunogenicity; Reactogenicity; Rotavirus vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN A; LIVE VACCINE; PENTACEL; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE;

ANOREXIA; ARTICLE; ASTHMA; BLOOD TOXICITY; BRONCHIOLITIS; CANADA; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN EXPERIMENT; HYPOVOLEMIA; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IRRITABILITY; KIDNEY CYST; LEUKOCYTOSIS; MALE; MENINGITIS; MESENTERIC LYMPHADENITIS; NORMAL HUMAN; PETIT MAL; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; SIDE EFFECT; UNITED STATES; VIRUS SHEDDING; VOMITING; WHEEZING;

EID: 20544449236     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000164763.55558.71     Document Type: Article

References (19)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9:565-572.
2. Ho MS, Glass RI, Pinsky PF, Anderson LJ. Rotavirus as a cause of diarrheal morbidity and mortality in the United States. J Infect Dis. 1988;158:1112-1116.
3. Institute of Medicine. Appendix D-13: the prospects for immunizing against rotavirus. In: New Vaccine Development, Establishing Priorities: Diseases of Importance in Developing Countries. Washington, DC: National Academy Press; 1986:308-318.
4. Kapikian AZ, Flores J, Hoshino Y, et al. Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a " Jennerian" approach to vaccination. J Infect Dis. 1986;153:815-822.
5. Advisory Committee on Immunization Practices. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999;48(RR-2):1-20.
6. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344:564-572.
7. Rennels MB, Parashar UD, Holman RC, Le CT, Chang HG, Glass RI. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr Infect Dis J. 1998;17:924-925.
8. Chang EJ, Zangwill KM, Lee H, Ward JI. Lack of association between rotavirus infection and intussusception: implications for use of attenuated rotavirus vaccines. Pediatr Infect Dis J. 2002;21:97-102.
9. Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL. Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis. 1991; 164(2):277-283.
10. Bernstein DI, Sack DA, Reisinger K, Rothstein E, Ward RL. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis. 2002;186:1487-1489.
11. Bernstein DI, Sack DA, Rothstein E, et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet. 1999;354:287-290.
12. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine. 1998;16: 381-387.
13. Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis. 1989;159:79-88.
14. Gouvea V, Glass RI, Woods P, et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol. 1990;28:276-282.
15. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics. 1996;97:7-13.
16. Joensuu I, Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr infect Dis J. 1998;17:334-340.
17. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med. 1996;335:1022-1028.
18. Rennels MB. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis. 1996;174(suppl 1):S107-S111.
19. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J. 2004;23:937-943.